SEARCH

SEARCH BY CITATION

Additional Supporting Information may be found in the online version of this article.

FilenameFormatSizeDescription
cncr28647-sup-0001-suppfig1.tiff23868KSupplemental Figure 1: Oncologic outcomes of clinically high-risk patients stratified by pathologic Gleason sum. A) biochemical recurrence, B) androgen deprivation therapy, C) metastases, D) prostate cancer specific survival
cncr28647-sup-0002-suppfig2.tiff23992KSupplemental Figure 2: Oncologic outcomes of clinically high-risk patients stratified by pathologic organ confined vs. non-organ confined. A) biochemical recurrence, B) androgen deprivation therapy, C) metastases, D) prostate cancer specific survival
cncr28647-sup-0003-suppfig3.tiff23802KSupplemental Figure 3: Oncologic outcomes of clinically high-risk patients stratified by pre-operative PSA. A) biochemical recurrence, B) androgen deprivation therapy, C) metastases, D) prostate cancer specific survival

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.